SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06500.0%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Williams who wrote (12056)6/11/2013 9:08:05 AM
From: boomertree22 Recommendations

Recommended By
Howard Williams
Jack Russell

  Read Replies (2) of 13111
 
Good paper. Highlights the importance of the Stage III trial protocol dosing determination in the success of treatment, particularly in patients with greater tumor burden and aggressive disease. Paper illustrates that PV-10 has systemic or bystander effect on untreated tumors, but immune response can't keep up with patients with heavy tumor burden and aggressive disease. Ideal dosing decision would allow more frequent dosing and injection of a greater number of tumors. This is supported by the impressive Phase II trial finding that "Among those patients who had all of their tumor burden treated, 54% had complete responses." I had not heard that finding before this paper.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News